BioMarin

YTD

ALL

Trade BioMarin 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About BMRN

BioMarin Pharmaceutical, Inc. engages in the development and commercialization of therapies for people with serious and life-threatening rare diseases and medical conditions. Its pipeline products include Valoctocogene roxaparvovec, Vosoritide, and BMN 307.

CEO

Alexander Hardy

CEOAlexander Hardy

Employees

3,221

Employees3,221

Headquarters

San Rafael, California

HeadquartersSan Rafael, California

Founded

1997

Founded1997

Employees

3,221

Employees3,221

BMRN Key Statistics

Market cap

10.62B

Market cap10.62B

Price-Earnings ratio

40.15

Price-Earnings ratio40.15

Dividend yield

—

Dividend yield—

Average volume

1.86M

Average volume1.86M

High today

$55.62

High today$55.62

Low today

$54.74

Low today$54.74

Open price

$55.04

Open price$55.04

Volume

645.60K

Volume645.60K

52 Week high

$66.28

52 Week high$66.28

52 Week low

$49.26

52 Week low$49.26

Stock Snapshot

The current BioMarin(BMRN) stock price is $54.97, with a market capitalization of 10.62B. The stock trades at a price-to-earnings (P/E) ratio of 40.15.

As of 2026-06-18, BioMarin(BMRN) stock has fluctuated between $54.74 and $55.62. The current price stands at $54.97, placing the stock +0.4% above today's low and -1.2% off the high.

The BioMarin(BMRN)'s current trading volume is 645.6K, compared to an average daily volume of 1.86M.

During the past year, BioMarin(BMRN) stock moved between $49.26 at its lowest and $66.28 at its peak.

BMRN News

TipRanks 1d

BioMarin’s IMPALA Study Aims to Boost Palynziq Value With Better Tolerability

Biomarin Pharmaceutical Inc. (BMRN) announced an update on their ongoing clinical study. Unlock powerful investing tools and data-driven insights with TipRanks...

Simply Wall St 2d

BioMarin Pharmaceutical Stock Could Be 36.7% Undervalued After ENDO 2026 Data

BioMarin Pharmaceutical (BMRN) drew fresh attention after presenting new VOXZOGO and BMN 333 data at ENDO 2026, reinforcing its focus on rare bone growth disord...

TipRanks 2d

BioMarin’s Voxzogo and BMN 333 show impact in hypochondroplasia, achondroplasia

BioMarin (BMRN) Pharmaceutical announced new data from studies of Voxzogo – vosoritide – in children with hypochondroplasia and the investigational medicine BMN...

Analyst ratings

79%

of 29 ratings

Buy

79.3%

Hold

20.7%

Sell

People also own

Based on the portfolios of people who own BMRN. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.